It has been learnt that in order to build technology that can avert disease-formation in the body, Genesis Research & Development is mulling over the prospect of signing a deal with a large investor.

It has been revealed by the Auckland-based bio-technology Company that it has entered into the final negotiations stage with a pharmaceutical and venture capital firm, with the aim to develop a subsidiary company that would focus on gene silencing.

According to the Chief Executive Stephen Hill, with the help of gene silencing, an individual’s genes can be turned off; thereby preventing them from making a protein that would otherwise cause a disease. This is being viewed as an extraordinary development in the times of economic crisis. 
 
Furthermore, a sum of nearly $1 million is being hoped to be raised by the company from shareholders to fund its other ventures. The shares of Genesis jumped 5.5 cents, or 60%, to 15c after the announcement on Wednesday.